| Literature DB >> 23444141 |
Branden S Moriarity1, Eric P Rahrmann, Vincent W Keng, Luke S Manlove, Dominic A Beckmann, Natalie K Wolf, Touba Khurshid, Jason B Bell, David A Largaespada.
Abstract
Studying complex biological processes such as cancer development, stem cell induction and transdifferentiation requires the modulation of multiple genes or pathways at one time in a single cell. Herein, we describe straightforward methods for rapid and efficient assembly of bacterial marker free multigene cassettes containing up to six complementary DNAs/short hairpin RNAs. We have termed this method RecWay assembly, as it makes use of both Cre recombinase and the commercially available Gateway cloning system. Further, because RecWay assembly uses truly modular components, it allows for the generation of randomly assembled multigene vector libraries. These multigene vectors are integratable, and later excisable, using the highly efficient piggyBac (PB) DNA transposon system. Moreover, we have dramatically improved the expression of stably integrated multigene vectors by incorporation of insulator elements to prevent promoter interference seen with multigene vectors. We demonstrate that insulated multigene PB transposons can stably integrate and faithfully express up to five fluorescent proteins and the puromycin-thymidine kinase resistance gene in vitro, with up to 70-fold higher gene expression compared with analogous uninsulated vectors. RecWay assembly of multigene transposon vectors allows for widely applicable modelling of highly complex biological processes and can be easily performed by other research laboratories.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23444141 PMCID: PMC3632113 DOI: 10.1093/nar/gkt115
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 19.160
Figure 1.Assembly of dual expression vectors via dual LR Clonase reaction. (a) Canonical Gateway cloning using the BP Clonase reaction to generate entry vectors (Left) and LR Clonase reaction to generate expression vectors (Right). (b) Initial dual DEST architecture that produces ∼50% correctly recombined clones on dual LR Clonase reaction with pENTR1 and pENTR2 plasmids. (c) Improved dual DEST architecture that produces >98% correctly recombined clones on dual LR Clonase reaction with pENTR1 and pENTR2 plasmids by addition of a kanamycin resistance gene between DEST1 and DEST2. (d) Diagram of BP Clonase reaction to generate pENTR 2 vectors from attB PCR products analogous to canonical Gateway cloning (Left). Diagram of the entry transfer system developed to move cDNAs/shRNAs from pENTR1 vectors into pENTR2 vectors via LR Clonase reaction (Right). This system was generated by inserting the DEST1 cassette with the attL sites of pENTR2 and replacing the kanamycin resistance with Tetracycline in pENTR2. (e) In addition to transferring cDNA/shRNAs between entry vectors, we also developed pENTR2-DEST1-IRES-Marker vectors to include useful selectable markers, such as puromycin, neomycin, hygromycin and fluorescent proteins.
Dual clonase efficiencies: results of all dual clonase reactions using vectors designed to prevent misrecombination by virtue of the bacterial drug resistance marker positioned between the two tandem DEST cassettes
| Vector | pENTR1 | Size (kb) | pENTR2 | Size (kb) | Correct Clones | % Correct |
|---|---|---|---|---|---|---|
| pDual DEST Shuttle (Cm) | DsRED2 | 0.82 | EGFP | 0.78 | 2/2 | 100 |
| pDual DEST Shuttle (Cm) | Venus | 0.78 | AmCyan | 0.75 | 3/4 | 75 |
| pPB-Dual DEST (Kan) | 4.53 | sh | 3.23 | 4/4 | 100 | |
| pPB-Dual DEST (Kan) | DsRED2 | 0.82 | EGFP | 0.78 | 4/4 | 100 |
| pPB-Dual DEST (Kan) | EGFP | 0.78 | DsRED2 | 0.82 | 4/4 | 100 |
| pPB-Dual DEST (Kan) | DsRED2 | 0.82 | EGFP-IRES-Puro/TK | 3.32 | 3/3 | 100 |
| pPB-Dual DEST (Kan) | LargeT Antigen | 2.81 | 0.61 | 4/4 | 100 | |
| pPB-Dual DEST (Kan) | sh | 3.23 | rtTA-IRES-Luc | 3.22 | 4/4 | 100 |
| pDual DEST Shuttle (Cm) | EGFP | 0.78 | Luciferase | 1.91 | 3/3 | 100 |
| pPB-Dual DEST (Kan) | 3.70 | sh | 3.23 | 2/2 | 100 | |
| pDual DEST Shuttle (Cm) | EGFP | 0.78 | DsRED2 | 0.82 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | DsRED2 | 0.82 | EGFP-IRES-Puro/TK | 3.32 | 2/2 | 100 |
| pDual DEST Shuttle (Cm) | EGFP | 0.78 | DsRED2 | 0.82 | 2/2 | 100 |
| pDual DEST Shuttle (Spec) | mYFP | 0.73 | AmCyan | 0.75 | 1/2 | 50 |
| pIDual DEST Shuttle (Spec) | mYFP | 0.73 | AmCyan | 0.75 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | DsRED2 | 0.82 | EGFP-IRES-Puro/TK | 3.32 | 2/2 | 100 |
| pPB-Dual DEST (Kan) | sh | 1.26 | sh | 3.23 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | mKate | 0.73 | Puro-TK | 1.99 | 2/2 | 100 |
| pPB-Dual DEST (Kan) | 4.53 | 3.56 | 2/2 | 100 | ||
| pPB-IDual DEST (Kan) | mKATE | 0.73 | Puro-TK | 1.99 | 2/2 | 100 |
| pDual DEST Shuttle (Spec) | mKATE | 0.73 | Puro-TK | 1.99 | 2/2 | 100 |
| pPB-Dual DEST (Kan) | mKATE | 0.73 | Puro-TK | 1.99 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | LargeT Antigen | 2.81 | 3.42 | 2/2 | 100 | |
| pDual DEST Shuttle (Spec) | eBFP2 | 0.73 | mOrange2 | 0.90 | 2/2 | 100 |
| pIDual DEST Shuttle (Spec) | eBFP2 | 0.73 | mOrange2 | 0.90 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | M2-rtTA | 0.77 | Puro-TK | 1.99 | 2/2 | 100 |
| pDual DEST Shuttle (Cm) | EGFP | 0.78 | mKATE | 0.73 | 2/2 | 100 |
| pPB-Dual DEST (Kan) | mKATE | 0.73 | EGFP | 0.78 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | mKATE | 0.73 | EGFP | 0.78 | 2/2 | 100 |
| pDual DEST Shuttle (Cm) | mKATE | 0.73 | EGFP | 0.78 | 2/2 | 100 |
| pDual DEST Shuttle (Cm) | EGFP | 0.78 | mKATE | 0.73 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | 4.53 | 3.56 | 2/2 | 100 | ||
| pIDual DEST Shuttle (Cm) | sh | 3.63 | 0.61 | 2/2 | 100 | |
| pIDual DEST Shuttle (Cm) | EGFP | 0.78 | Luciferase | 1.91 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | 1.30 | Luciferase | 1.91 | 1/1 | 100 | |
| pPB-IDual DEST (Kan) | LargeT Antigen | 2.81 | 0.61 | 2/2 | 100 | |
| pDual DEST Shuttle (Cm) | mYFP | 0.73 | AmCyan | 0.75 | 2/2 | 100 |
| pIDual DEST Shuttle (Cm) | mYFP | 0.73 | AmCyan | 0.75 | 2/2 | 100 |
| pPB-Dual DEST (Kan) | mYFP | 0.73 | mKATE | 0.73 | 2/2 | 100 |
| pPB-IDual DEST (Kan) | mYFP | 0.73 | mKATE | 0.73 | 2/2 | 100 |
| 91/93 | 98.10% | |||||
Figure 2.Assembly of up to 6 gene vectors using Cre Recombinase. (a) Diagram of the two dual DEST Shuttle vectors used to subsequently generate four or six gene vectors after dual LR Clonase reaction. The Cre recombinase LoxP and Lox2722 mutant are represented as black and white triangles, respectively. (b) Diagram of vector layout of the insulated versions of the shuttle vectors and final PB dual DEST vectors are also shown. (c) Schematic of steps to generate bacterial marker-free six gene transposon vectors using RecWay assembly. Three dual clonase reactions are performed using two shuttle vectors and a single transposon dual DEST vector. I-SceI digestion and self-ligation of shuttle vectors containing the cDNAs/shRNAs of interest is performed followed by retrofitting via Cre recombination of all three dual vectors. Once assembled, vectors can be transformed into FLP recombinase-expressing bacteria to remove the KanR (kanamycin), CmR (chloramphenicol) and SpecR (spectinomycin) bacterial markers flanked by unique FRT sites (FRT1, 3 and 14, respectively). The FRT sites and insulators are not shown for simplicity; see Supplementary Figure S1a and b for a more highly detailed schematic representation. (d) Seven-day timeline for the assembly of bacterial marker-free six gene transposon vectors using RecWay assembly.
Cre recombinase efficiencies: results of all retrofitting reactions performed between final transposon vectors and shuttle vectors with ColE elements removed by I-SceI digest
| Expression Vector | Size (kb) | Shuttle Vector | Size (kb) | Final Size (kb) | Correct Clones | % Correct |
|---|---|---|---|---|---|---|
| pPB-Dual-EXP-EGFP/DsRED2 (Kan) | 9.75 | pDual Shuttle-Venus/AmCyan (Cm) | 7.59 | 17.34 | 8/8 | 100 |
| pPB-Dual-EXP-LgT/ | 15.20 | pDual Shuttle-EGFP/Luciferase (Cm) | 8.74 | 23.95 | 3/4 | 75 |
| pPB-Dual-EXP-EGFP/DsRED2 (Kan) | 9.75 | pDual Shuttle-EGFP/DsRED2 (Cm) | 10.23 | 19.99 | 2/2 | 100 |
| pPB-Dual-EXP-EGFP/DsRED2 (Kan) | 9.75 | pDual Shuttle-mYFP/AmCyan (Spec) | 7.53 | 17.28 | 1/2 | 50 |
| pPB-IDual-EXP-mKATE/Puro-TK (Kan) | 16.63 | pIDual Shuttle-mYFP/AmCyan (Spec) | 12.98 | 29.61 | 1/1 | 100 |
| pPB-IDual-EXP-mKATE/Puro-TK (Kan) | 16.63 | pIDual Shuttle-EGFP/DsRED2 (Cm) | 10.23 | 26.87 | 2/2 | 100 |
| pPB-IDual-EXP-mKATE/Puro-TK (Kan) | 16.63 | pIDual Shuttle-EGFP/DsRED2 (Cm) | 10.23 | 26.87 | 2/2 | 100 |
| pPB-Dual-EXP-mKATE/Puro-TK (Kan) | 11.53 | pDual Shuttle-EGFP/DsRED2 (Cm) | 10.23 | 21.77 | 2/2 | 100 |
| pPB-Dual-EXP-mKATE/Puro-TK (Kan) | 11.53 | pDual Shuttle-mYFP/AmCyan (Spec) | 7.53 | 19.06 | 1/1 | 100 |
| pPB-Quad-EXP-mYFP/AmCyan/mKATE/Puro-TK (Kan)(Spec) | 17.64 | pDual Shuttle-EGFP/DsRED2 (Cm) | 10.23 | 27.88 | 2/2 | 100 |
| PB-IQuad-EXP-EGFP/DsRED2/mKATE/Puro-TK | 22.58 | pIDual Shuttle-mYFP/AmCyan (Spec) | 12.98 | 35.56 | 1/1 | 100 |
| pPB-Dual-EXP-mKATE/Puro-TK | 9.82 | pDual Shuttle-eBFP2/mOrange2 (Spec) | 7.84 | 17.66 | 2/2 | 100 |
| pPB-IDual-EXP-mKATE/Puro-TK | 16.63 | pIDual Shuttle-eBFP2/mOrange2 (Spec) | 12.94 | 29.58 | 2/2 | 100 |
| PB-Quad-EXP-eBFP2/mOrange2/mKATE/Puro-TK | 14.68 | pDual Shuttle-mYFP/AmCyan (Cm) | 7.53 | 22.21 | 2/2 | 100 |
| PB-IQuad-EXP-eBFP2/mOrange2/mKATE/Puro-TK | 24.88 | pIDual Shuttle-mYFP/AmCyan (Cm) | 10.10 | 34.98 | 1/2 | 50 |
| pPB-Dual-EXP-mKATE/Puro-TK | 9.82 | pDual Shuttle-mYFP/AmCyan (Cm) | 7.53 | 17.35 | 2/2 | 100 |
| pPB-IDual-EXP-mKATE/Puro-TK (Kan) | 16.63 | pIDual Shuttle-mYFP/AmCyan (Cm) | 10.10 | 26.74 | 2/2 | 100 |
| 36/39 | 92.60% | |||||
All clones were analysed and confirmed as correct or incorrect by standard RE digest analysis.
Figure 3.Expression of stably integrated multigene transposon vectors in NIH 3T3 cells. (a) Diagram of vectors containing one, three or five fluorescent proteins along with the puromycin-tk (puro-tk) fusion. (b) Representative fluorescence photomicrographs and QRT-PCR analysis of stably integrated insulated and uninsulated multigene vectors. Expression levels are normalized to uninsulated vector gene expression for direct comparison of insulated and uninsulated vectors. P-values were calculated using a two-tailed unpaired t-test (P > 0.0001***, P > 0.001**, P > 0.01*).
Figure 4.Transposition efficiency of multigene vectors. (a,b) Bar graph demonstrating the number of puromycin-resistant stable integration clones generated in HEK293T cells after transfection of transposase and insulated or uninsulated transposon vectors. (c) Representative sequencing results of PB splinkerette analysis of stable transposon integration cell lines with each vector tested. All cloned insertion sites contained inverted terminal repeat sequence, canonical TTAA insertion site sequence and adjacent genomic sequence.
Figure 5.Hydrodynamic injection of PB multigene vectors induce liver cancer in the Fah-deficient mouse model. (a) Multigene PB transposon vector used for hydrodynamic tail vein injection. PB-Quad-EXP-shTrp53/NRASG12V/Fah/Luc, short hairpin to Trp53, constitutively active NRASG12V cDNA, fumarylacetoacetate hydrolase (Fah) cDNA and Luciferase cDNA all under the control of independent human elongation factor 1 alpha (EF1A) promoters. (b) Representative luciferase imaging of a mouse two weeks post-hydrodynamic injection. (c) Gross examination of the liver on necropsy identified numerous tumour nodules that were formalin fixed for H&E and immunohistochemical analysis. (d) Immunohistochemical staining results for NRAS, Fah and Ki-67 with appropriate no primary controls. T, tumour; P, parenchyma; higher magnification shown as insert box.